<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03351517</url>
  </required_header>
  <id_info>
    <org_study_id>T/IM-NF/Pharma/02/17</org_study_id>
    <nct_id>NCT03351517</nct_id>
  </id_info>
  <brief_title>Preemptive Tapentadol on Post-operative Analgesia Following Total Knee Arthroplasty</brief_title>
  <official_title>Preemptive Tapentadol on Post-operative Analgesia Following Total Knee Arthroplasty: A Randomized Double Blind Placebo-controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>All India Institute of Medical Sciences, Bhubaneswar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>All India Institute of Medical Sciences, Bhubaneswar</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study intends to evaluate the efficacy of Tapentadol against placebo as a preemptive&#xD;
      analgesic in the management of post-operative pain in the patiens undergoing total knee&#xD;
      arthroplasty.&#xD;
&#xD;
      The primary objective is to evaluate th epain score in visual analogue scale at various time&#xD;
      points within 24 hours post operarively&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      METHODOLOGY&#xD;
&#xD;
        -  Consent: Participants will be explained the benefit and harm of joining the study and&#xD;
           the freedom of withdrawing from the study at any moment they would like to. A full&#xD;
           voluntary written informed consent will be obtained from each participant. Study will be&#xD;
           conducted following the principles of Helsinki after getting written permission of the&#xD;
           institutional ethics committee. Before enrolment of first subject in this study&#xD;
           registration for clinical trial will be done.&#xD;
&#xD;
        -  Participants: Patients of either sex, above 18 yrs. of age undergoing Total Knee&#xD;
           Arthroplasty will be the participants in this study.&#xD;
&#xD;
           1. Inclusion Criteria:&#xD;
&#xD;
        -  Patients both males and females undergoing elective total knee replacement surgery&#xD;
&#xD;
        -  Patients are capable to provide an informed consent&#xD;
&#xD;
        -  Age 18-75 yrs.&#xD;
&#xD;
           2. Exclusion Criteria:&#xD;
&#xD;
        -  Patients with Asthma, COPD or any other respiratory disease.&#xD;
&#xD;
        -  Persistent nausea and vomiting at the time of randomization.&#xD;
&#xD;
        -  Epilepsy.&#xD;
&#xD;
        -  Treated with mono amine oxidase inhibitors, tricyclic antidepressants, serotonin&#xD;
           norepinephrine re uptake inhibitors.&#xD;
&#xD;
        -  Patients with ASA grading 3 or more.&#xD;
&#xD;
        -  Drug abuse history.&#xD;
&#xD;
        -  Opioid tolerance or opioid dependence.&#xD;
&#xD;
        -  Renal disease(creatinine&gt;1.5 mg/dl).&#xD;
&#xD;
        -  Liver disease (total bilirubin&gt;1.5 mg/dl).&#xD;
&#xD;
        -  Known history of opioid allergies.&#xD;
&#xD;
        -  Major psychiatric disorder.&#xD;
&#xD;
        -  Pregnancy and lactation.&#xD;
&#xD;
        -  Emergency surgery.&#xD;
&#xD;
        -  Bone tumor&#xD;
&#xD;
        -  Migraine patients or patients complaining dizziness, vertigo.&#xD;
&#xD;
      Screening: The trial will be comprised of complete medical history and physical examination&#xD;
      and screening. Pre-operative laboratory investigations will be recorded in case record form.&#xD;
&#xD;
        -  Randomization: A total of 90 Participants will be selected by computer generated random&#xD;
           list.&#xD;
&#xD;
        -  Blinding: The study will be conducted in a double blinded manner.&#xD;
&#xD;
        -  Treatment Administration and baseline follow up: The participants will be assigned to&#xD;
           receive 100 mg of Tapentadol or a matched placebo orally 1 hr before spinal anesthesia&#xD;
           in a double-blind manner. All the participants, both control and Tapentadol group will&#xD;
           be anesthetized (SP) as per the standard protocol after similar pre-medication. Single&#xD;
           dose of injection Paracetamol 1 gm i.v. will be provided in both the groups immediately&#xD;
           after operation.&#xD;
&#xD;
        -  Assessment of efficacy and safety and Duration: All the subjects will be assessed for&#xD;
           pain at rest, before surgery, at 0, 6 12 &amp;, 24 hrs. post operatively by visual analogue&#xD;
           scale score(VAS) (0 mm: no pain,100 mm: Worst pain imaginable).16 and TOTPAR&#xD;
           SCALE(None-Mild-Moderate-Severe) *. They also will be evaluated for nausea, vomiting,&#xD;
           drowsiness, and pruritus and will be rated on0,6,12, &amp; 24 hrs.16. Total rescue analgesic&#xD;
           consumption also will be assessed at 24 hrs post operatively 16. The time of 1st request&#xD;
           for supplemental analgesia also will be recorded. A blood sample will be obtained from&#xD;
           each participant at 0 hrs. post operatively to measure the tapentadol concentration and&#xD;
           Cholecystokinin by ELISA method.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Actual">September 7, 2018</completion_date>
  <primary_completion_date type="Actual">August 20, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of Change of Pain score compared to plecebo by visual analogue scale</measure>
    <time_frame>24 hrs. post-operatively( 0,2,4,6,12,24 hrs post operatively)</time_frame>
    <description>All the subjects will be assessed for pain at various time points post-operatively by visual analogue scale(VAS) (minimum value 00- no pain to maximum value-100 - worst pain imaginable) Higher values indicate worse outcome</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Analgesia</condition>
  <arm_group>
    <arm_group_label>Tapentadol arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 100 mg of extended release oral tapentadol will be administered 1 hour before surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A comparable placebo will be administered 1 hour before surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tapentadol 100 MG</intervention_name>
    <description>100 mg of oral extended release tapentadol will be given to the patients undergoing total knee replacement surgery on spinal anesthesia to evaluate its efficacy in the management of post-operative pain.</description>
    <arm_group_label>Tapentadol arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>A matching placebo will be given to the patients undergoing total knee replacement surgery on spinal anesthesia to evaluate its efficacy in the management of post-operative pain.</description>
    <arm_group_label>Placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients of either sex undergoing elective tota knee replacement surgery&#xD;
&#xD;
          -  Patients are capable to provide an informed consent&#xD;
&#xD;
          -  Age 18-65 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with Asthma, copd or any other respiratory disease&#xD;
&#xD;
          -  Persistent nausea , vomiting at the time of randomization&#xD;
&#xD;
          -  Treated with MAO inhibitors, Tricyclic antidepressants, SSRIs and SNRIs&#xD;
&#xD;
          -  Patients with ASA grading 3 or more&#xD;
&#xD;
          -  Drug abuse history, opioid tolerance or dependence, known history of opiod allergies&#xD;
&#xD;
          -  Renal or liver disease&#xD;
&#xD;
          -  Major psychiatric disorder&#xD;
&#xD;
          -  Pregnancy and lactation&#xD;
&#xD;
          -  Emergency surgery&#xD;
&#xD;
          -  Bone tumor, epilepsy or patients with migraine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>DEBASISH HOTA, MD,DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>AIIMS Bhubaneswar</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>All India Institute of Medical Sciences</name>
      <address>
        <city>Bhubaneswar</city>
        <state>Odisha</state>
        <zip>751019</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>November 11, 2017</study_first_submitted>
  <study_first_submitted_qc>November 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2017</study_first_posted>
  <last_update_submitted>September 7, 2018</last_update_submitted>
  <last_update_submitted_qc>September 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>All India Institute of Medical Sciences, Bhubaneswar</investigator_affiliation>
    <investigator_full_name>Dr Debasish Hota</investigator_full_name>
    <investigator_title>Prof and Head of the Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Agnosia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tapentadol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

